Nanomaterials in Cancers Therapy
A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Applied Biosciences and Bioengineering".
Deadline for manuscript submissions: 20 January 2026 | Viewed by 44
Special Issue Editor
Interests: tissue engineering; nanobiotechnology; microbiology; siRNA; antimicrobials
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is a global issue causing death. Though many types of treatments are available, the effective and safe delivery of drugs to target tissues still needs attention. Fortunately, nanomaterials have great potential to address these problems. Nanomaterials fall between 1 and 100 nm in size with unique optical, magnetic, and electrical properties. Being very small gives them many advantages in terms of their behavior and applications. They have thus found applications in a variety of cancer treatments aimed at overcoming drug toxicity, addressing the lack of selectivity, increasing bioavailability, etc. While the surface modifications of nanomaterials allow for the active targeting of tumor cells, their nanoscale size enhances their permeability and retention for passive targeting. A variety of nanomaterials are being used for cancer therapeutics such as metallic (gold, silver, etc.), polymeric (PLGA, PLA, etc.), carbon-based (carbon nanotubes, graphene, fullerenes, etc.), ceramic-based (silicon dioxide, alumina, and other metal oxides), and biological nanomaterials (proteins, lipids, nucleic acid, etc.). These nanomaterials are being used as drug carriers, gene carriers, chemotherapeutics, photosensitizers, etc. They are also involved in multifunctional strategies like gene silencing, immunotherapy, and photothermal therapy. Numerous FDA-approved nano-formulations have been developed to treat complex diseases, including advanced non-small-cell lung cancer, primary metastatic pancreatic cancer, secondary metastatic breast cancer, ovarian cancer, multiple myeloma, leukemia, amyloidosis, AIDS-related Kaposi's sarcoma, and age-related macular degeneration. The US Food and Drug Administration (FDA) authorized a liposomal version of doxorubicin in 1995 for the treatment of Kaposi sarcoma associated with AIDS and the clinical use of protein-bound paclitaxel (Abraxane), an albumin-based nanoparticle, in 2005 for the treatment of pancreatic, non-small-cell lung, and breast cancer. In 2012, the FDA authorized Marqibo for leukemia, and Vyxeos was licensed in 2017 for the treatment of newly diagnosed acute myeloid leukemia (AML) associated with therapy or AML with myelodysplasia-related alterations. Many other nanomaterials are under clinical trial for cancer therapy. However, this field is still in its preliminary stages, and a large number of challenges remain to be addressed to accelerate nanomaterial translations.
Dr. Komal Vig
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomaterial
- cancer
- drug
- therapeutics
- therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
